Literature DB >> 21575882

Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study.

I Blumenstein1, E Herrmann, N Filmann, C Zosel, W Tacke, H Bock, A Dignass, F Hartmann, S Zeuzem, J Stein, O Schröder.   

Abstract

BACKGROUND: The introduction of immunosuppressants and biologic agents has led to active debate and research about optimal therapeutic strategies considering risk factors and predictors of clinical outcome in inflammatory bowel disease (IBD). Data about gender-specific treatment differences and risk factors is lacking for IBD. The aim of the present study was to evaluate gender-related differences in the treatment of a distinct IBD patient population treated in the Rhein-Main region, Germany.
METHODS: Data about past medical history, disease status and medical treatment of 986 outpatients treated in ten gastroenterological practices and three hospitals were collected from November 1st 2005-July 31st 2007 and analyzed with regard to gender-related differences in therapy and disease management.
RESULTS: With the exception of an extended disease duration in women, no significant gender-related differences in demographic and clinical characteristics were observed. Men showed a significantly higher remission rate than women (p=0.025), while women received significantly less immunosuppressive medication compared to men (p=0.011). In addition, treatment with immunosuppressants was not different in women with child-bearing potential compared to menopausal women.
CONCLUSION: Our investigation demonstrates for the first time gender-specific differences in the therapeutic management in a large cohort of IBD patients.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21575882     DOI: 10.1016/j.crohns.2010.12.012

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  18 in total

Review 1.  Reproductive Planning and Contraception for Women with Inflammatory Bowel Diseases.

Authors:  Lori M Gawron; Jessica Sanders; Katelyn P Steele; Ann D Flynn
Journal:  Inflamm Bowel Dis       Date:  2016-02       Impact factor: 5.325

2.  Documentation of reproductive health counseling and contraception in women with inflammatory bowel diseases.

Authors:  Lori M Gawron; Cassing Hammond; Laurie Keefer
Journal:  Patient Educ Couns       Date:  2013-09-27

3.  A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype.

Authors:  Sharif Yassin; Naomi Fliss Isakov; Yulia Ron; Nathaniel Aviv Cohen; Ayal Hirsch; Nitsan Maharshak
Journal:  Int J Colorectal Dis       Date:  2021-01-06       Impact factor: 2.571

4.  Sex Differences in Experimentally Induced Colitis in Mice: a Role for Estrogens.

Authors:  Janka Bábíčková; Ľubomíra Tóthová; Eva Lengyelová; Anastázie Bartoňová; Július Hodosy; Roman Gardlík; Peter Celec
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

5.  Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey.

Authors:  Lea I Kredel; Oliver Schneidereit; Jörg C Hoffmann; Britta Siegmund; Jan C Preiß
Journal:  Int J Colorectal Dis       Date:  2018-12-07       Impact factor: 2.571

6.  Ileitis-associated tertiary lymphoid organs arise at lymphatic valves and impede mesenteric lymph flow in response to tumor necrosis factor.

Authors:  Rafael S Czepielewski; Emma C Erlich; Emily J Onufer; Shannon Young; Brian T Saunders; Yong-Hyun Han; Mary Wohltmann; Peter L Wang; Ki-Wook Kim; Shashi Kumar; Chyi-Song Hsieh; Joshua P Scallan; Ying Yang; Bernd H Zinselmeyer; Michael J Davis; Gwendalyn J Randolph
Journal:  Immunity       Date:  2021-11-16       Impact factor: 31.745

7.  Colitis-induced bone loss is gender dependent and associated with increased inflammation.

Authors:  Regina Irwin; Taehyung Lee; Vincent B Young; Narayanan Parameswaran; Laura R McCabe
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

8.  Assessment of Sex Differences for Treatment, Procedures, Complications, and Associated Conditions Among Adolescents Hospitalized with Crohn's Disease.

Authors:  Jennifer L Dotson; Josh B Bricker; Michael D Kappelman; Deena Chisolm; Wallace V Crandall
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325

9.  Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients.

Authors:  Lindsay A Sceats; Arden M Morris; M Kate Bundorf; K T Park; Cindy Kin
Journal:  Dis Colon Rectum       Date:  2019-05       Impact factor: 4.585

10.  Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease.

Authors:  Victor K Tso; Beate C Sydora; Rae R Foshaug; Thomas A Churchill; Jason Doyle; Carolyn M Slupsky; Richard N Fedorak
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.